Background: Platelet endothelial aggregation receptor 1 (PEAR1) may affect platelet-platelet contact
and aggregation. The aim of this study was to assess the association between PEAR1 polymorphisms and risks of
Methods: We searched the PubMed, EmBase, and Cochrane Library electronic databases for articles published
through November 30th. 2016. Meta-analysis was performed to examine the relationship between PEAR1 and
platelet aggregation and sensitivity analysis by removing individual study from meta-analysis. We collected and
analyzed the results of 5 trials involving 5466 patients.
Results: Our results demonstrated that the G allele of rs12041331 was associated with a greater platelet aggregation
by multiple agonists, both in the presence and absence of antiplatelet drugs, in several separate cohorts of
different ethnicities along with an apparent allelic dose–response effect. However, the results of studies on
rs2768759 locus were inconsistent and further studies are required. In the presence or absence of antiplatelet
drugs treatment, the lowest platelet aggregation was observed in rs2768759 wild-type (AA) patients, followed by
heterozygous (AC) and homozygous mutant (CC).
Conclusion: PEAR1 rs12041331 is associated with platelet function and antiplatelet drug pharmacodynamics.
Future studies on relationship between single nucleotide polymorphisms of PEAR1 and incidence of cardiovascular
diseases are required.